Results showed that in patients with hormone receptor positive disease who had an Oncotype DX Recurrence Score(TM) result greater than 18 (i.e., who were classified as intermediate risk of recurrence or above), a number of candidate genes strongly predicted benefit from treatment with docetaxel (Taxotere), a type of taxane commonly used for breast cancer therapy. A genomic classifier predicting differential benefit was identified and, if validated through additional studies, might be useful in defining differential benefit of docetaxel.
"We continue to gain meaningful insight into the biology of breast cancer and now, possibly, treatment benefit for a common taxane regimen with our ongoing study of the utility of Oncotype DX and additional breast cancer genes," said Lori J. Goldstein, M.D., Director of the Breast Evaluation Center at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and lead author of the study. "Further research to narrow down which genes are most predictive and validate their use could potentially yield a new panel of genes that may predict the benefit of treatment with docetaxel."
About Oncotype DX(R)
Oncotype DX is the first and only multi-gene expression test
commercially available that has clinical evidence validating its ability to
predict the likelihood of chemotherapy benefit as well as recurrence in
early-stage breast cancer. Oncotype DX has been extensively evaluated in
multiple independent studies involving more than 3,600 breast cancer
patients, including a large validation study published in The New England
Journal of Medicine and a chemotherapy benefit study published in the
Journal of Clinical Oncology. To date, 7,500 physicians have ordered more
than 55,000 tests, and health plans covering over 80 percent of U.S.
insured lives provide reimbursement for Oncotype DX through contracts,
agreements and policy decisions. Both the Ameri
|SOURCE Genomic Health, Inc.|
Copyright©2008 PR Newswire.
All rights reserved